Clinical Trial Update: A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II dose-finding study assessing safety and efficacy of LDE225 plus INC424 in myelofibrosis patients completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• INC424 (nilotinib)
• LDE225 (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis, Thrombocytosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-04-15